Key points from article :
Preliminary data that show its ERA™ (Epigenetic Reprogramming of Aging) treatment rejuvenates skin cells more effectively and safely than existing treatments.
ERA platform uses mRNA to deliver transcription factors to the epigenome.
Delivered with proprietary eTurna™ lipid-based delivery platform to target specific organs, tissues, and cell types.
Therapy increased fibroblasts and collagen VII to restore the production of collagen and elastin.
Also, reduced inflammation markers, oxidative stress, senescence, and MMPs (matrix metallopeptidases or matrixins).
Preclinical data were presented to dermatologists and industry KOLs attending four global conferences.
"[therapy] shows reversal from the effects of aging and offers an ability to improve the overall quality of the skin," - Anja Krammer, Turn Bio CEO.
Company has committed to releasing additional data during a January webinar.
